{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"0.8"},{"groupId":"OG002","value":"1.8"},{"groupId":"OG003","value":"1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"229"},{"groupId":"OG003","value":"196"}],"units":"Participants"}],"description":"To compare the rate of FN among low-risk participants registered at intervention components versus usual care components. Febrile neutropenia is defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) as an absolute neutrophil count (ANC) \\< 1000/µL and a single temperature of \\> 38.3°C (101°F) or a sustained temperature of ≥ 38°C (101°F) for more than one hour.","groups":[{"description":"CSF prescribing for patients taking anti-cancer drugs is based on existing automated system recommendations: CSF is recommended for drugs with high risk of FN; CSF is not recommended for drugs with low risk of FN.\n\nPreventive Intervention: Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Active Comparator: Clinic Group 1 (Clinics With Existing Automated System for CSF Prescribing)"},{"description":"CSF prescribing for patients taking anti-cancer drugs is based on existing clinical practice guidelines.\n\nPreventive Intervention: Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Active Comparator: Clinic Group 2 (Clinics With no Automated System for CSF Prescribing)"},{"description":"CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drugs with intermediate or high risk of FN; CSF is not recommended for drugs with low risk of FN.\n\nPreventive Intervention: Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG002","title":"Experimental: Clinic Group 3 (Clinics With Automated System for CSF Prescribing)"},{"description":"CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drug with high risk of FN; CSF is not recommended for drugs with intermediate or low risk of FN.\n\nPreventive Intervention: Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG003","title":"Experimental: Clinic Group 4 (Clinics With Automated System for CSF Prescribing)"}],"paramType":"NUMBER","populationDescription":"The analysis population includes only participants deemed 'low-risk' within each of the clinic groups.","reportingStatus":"POSTED","timeFrame":"Within 6 months of registration","title":"Incidence of Febrile Neutropenia Among Low Risk Participants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}